About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 815269, 14 pages
http://dx.doi.org/10.1155/2011/815269
Review Article

Gefitinib in Non Small Cell Lung Cancer

1Medical Oncology Unit, Thoraco-Pulmonary Department, National Cancer Institute, 80131 Napoli, Italy
2Clinical Trials Unit, National Cancer Institute, 80131 Napoli, Italy
3Medical Oncology Unit, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy
4Direzione Scientifica, National Cancer Institute, 80131 Napoli, Italy
5Thoracic Surgery, Thoraco-Pulmonary Department, National Cancer Institute, 80131 Napoli, Italy
6Cellular Biology and Biotherapy, National Cancer Institute, 80131 Napoli, Italy
7Centro di Ricerche Oncologiche di Mercogliano (CROM), 83013 Mercogliano, Italy

Received 17 December 2010; Accepted 15 March 2011

Academic Editor: Cesare Gridelli

Copyright © 2011 Raffaele Costanzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Baselga and S. D. Averbuch, “ZD1839 (‘Iressa’) as an anticancer agent,” Drugs, vol. 60, supplement 1, pp. 33–40, 2000. View at Scopus
  2. N. Normanno, C. Bianco, L. Strizzi et al., “The ErbB receptors and their ligands in cancer: an overview,” Current Drug Targets, vol. 6, no. 3, pp. 243–257, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. A. Olayioye, R. M. Neve, H. A. Lane, and N. E. Hynes, “The ErbB signaling network: receptor heterodimerization in development and cancer,” The EMBO Journal, vol. 19, no. 13, pp. 3159–3167, 2000. View at Scopus
  4. A. Wells, “EGF receptor,” International Journal of Biochemistry and Cell Biology, vol. 31, no. 6, pp. 637–643, 1999. View at Publisher · View at Google Scholar
  5. A. De Luca, A. Carotenuto, A. Rachiglio et al., “The role of the EGFR signaling in tumor microenvironment,” Journal of Cellular Physiology, vol. 214, no. 3, pp. 559–567, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. E. Wakeling, S. P. Guy, J. R. Woodburn et al., “ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy,” Cancer Research, vol. 62, no. 20, pp. 5749–5754, 2002. View at Scopus
  7. F. Ciardiello, R. Caputo, R. Bianco et al., “Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor,” Clinical Cancer Research, vol. 6, no. 5, pp. 2053–2063, 2000. View at Scopus
  8. F. M. Sirotnak, M. F. Zakowski, V. A. Miller, H. I. Scher, and M. G. Kris, “Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase,” Clinical Cancer Research, vol. 6, no. 12, pp. 4885–4892, 2000. View at Scopus
  9. H. Swaisland, A. Laight, L. Stafford et al., “Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers,” Clinical Pharmacokinetics, vol. 40, no. 4, pp. 297–306, 2001. View at Scopus
  10. M. Ranson, L. A. Hammond, D. Ferry et al., “ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial,” Journal of Clinical Oncology, vol. 20, no. 9, pp. 2240–2250, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Baselga, D. Rischin, M. Ranson et al., “Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types,” Journal of Clinical Oncology, vol. 20, no. 21, pp. 4292–4302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. R. S. Herbst, A. M. Maddox, M. L. Rothenberg et al., “Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial,” Journal of Clinical Oncology, vol. 20, no. 18, pp. 3815–3825, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Nakagawa, T. Tamura, S. Negoro et al., “Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors,” Annals of Oncology, vol. 14, no. 6, pp. 922–930, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Giaccone, J. L. González-Larriba, A. T. van Oosterom et al., “Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors,” Annals of Oncology, vol. 15, no. 5, pp. 831–838, 2004. View at Publisher · View at Google Scholar
  15. M. Fukuoka, S. Yano, G. Giaccone et al., “Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial),” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2237–2246, 2003. View at Publisher · View at Google Scholar · View at PubMed
  16. M. G. Kris, R. B. Natale, R. S. Herbst et al., “Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial,” Journal of the American Medical Association, vol. 290, no. 16, pp. 2149–2158, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. G. D'Addario, D. Rauch, R. Stupp et al., “Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03,” Annals of Oncology, vol. 19, no. 4, pp. 739–745, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. M. Z. Wang, L. Y. Li, S. L. Wang, et al., “Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer,” Chinese Medical Journal, vol. 119, no. 1, pp. 63–68, 2006. View at Scopus
  19. W. C. Lin, C. H. Chiu, J. L. Liou, et al., “Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer,” Lung Cancer, vol. 54, no. 2, pp. 193–199, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. S. Niho, K. Kubota, K. Goto et al., “First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 64–69, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Reck, E. Buchholz, K. S. Romer, et al., “Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer,” Clinical Lung Cancer, vol. 7, no. 6, pp. 406–411, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Suzuki, Y. Hasegawa, K. Baba et al., “A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer,” British Journal of Cancer, vol. 94, no. 11, pp. 1599–1603, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. D. R. Spigel, J. D. Hainsworth, E. R. Burkett et al., “Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a minnie pearl cancer research network phase II trial,” Clinical Lung Cancer, vol. 7, no. 2, pp. 127–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Giaccone, R. S. Herbst, C. Manegold et al., “Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 777–784, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. S. Herbst, G. Giaccone, J. H. Schiller et al., “Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 785–794, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. U. Gatzemeier, A. Pluzanska, A. Szczesna et al., “Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1545–1552, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. R. S. Herbst, D. Prager, R. Hermann et al., “TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5892–5899, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. A. Morabito, M. C. Piccirillo, K. Monaco, et al., “Methodological issues of clinical research with EGFR inhibitors,” Current Cancer Therapy Reviews, vol. 3, no. 4, pp. 292–302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Takeda, T. Hida, T. Sato et al., “Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203),” Journal of Clinical Oncology, vol. 28, no. 5, pp. 753–760, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. N. Thatcher, A. Chang, P. Parikh et al., “Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer),” The Lancet, vol. 366, no. 9496, pp. 1527–1537, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr. et al., “Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 5034–5042, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. T. Cufer, E. Vrdoljak, R. Gaafar, et al., “Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer,” Anti-Cancer Drugs, vol. 17, no. 4, pp. 401–409, 2006.
  33. E. S. Kim, V. Hirsh, T. Mok et al., “Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial,” The Lancet, vol. 372, no. 9652, pp. 1809–1818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Y. Douillard, F. A. Shepherd, V. Hirsh et al., “Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 744–752, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. R. Maruyama, Y. Nishiwaki, T. Tamura et al., “Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4244–4252, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. D. H. Lee, K. Park, J. H. Kim et al., “Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy,” Clinical Cancer Research, vol. 16, no. 4, pp. 1307–1314, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. F. A. Shepherd, J. Douillard, M. Fukuoka, et al., “Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): meta-analysis from four clinical trials,” Journal of Clinical Oncology, vol. 27, no. 15, supplement, 2009, (abstract no. 8011).
  38. G. D. Goss, I. Lorimer, M. S. Tsao, et al., “A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19,” Journal of Clinical Oncology, vol. 28, no. 18, supplement, 2010, (abstract no. LBA7005).
  39. K. Kelly, K. Chansky, L. E. Gaspar et al., “Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2450–2456, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. L. Crinò, F. Cappuzzo, P. Zatloukal et al., “Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4253–4260, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. G. Goss, D. Ferry, R. Wierzbicki et al., “Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status,” Journal of Clinical Oncology, vol. 27, no. 13, pp. 2253–2260, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. H. Asahina, K. Yamazaki, I. Kinoshita et al., “A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations,” British Journal of Cancer, vol. 95, no. 8, pp. 998–1004, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. A. Inoue, T. Suzuki, T. Fukuhara et al., “Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations,” Journal of Clinical Oncology, vol. 24, no. 21, pp. 3340–3346, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. C. H. Yang, C. J. Yu, J. Y. Shih et al., “Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy,” Journal of Clinical Oncology, vol. 26, no. 16, pp. 2745–2753, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. L. V. Sequist, R. G. Martins, D. Spigel et al., “First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2442–2449, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. A. Sutani, Y. Nagai, K. Udagawa et al., “Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp,” British Journal of Cancer, vol. 95, no. 11, pp. 1483–1489, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. K. Yoshida, Y. Yatabe, J. Y. Park et al., “Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 2, no. 1, pp. 22–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Sunaga, Y. Tomizawa, N. Yanagitani et al., “Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy,” Lung Cancer, vol. 56, no. 3, pp. 383–389, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. K. Tamura, I. Okamoto, T. Kash II et al., “Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403),” British Journal of Cancer, vol. 98, no. 5, pp. 907–914, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. K. Sugio, H. Uramoto, T. Onitsuka et al., “Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations,” Lung Cancer, vol. 64, no. 3, pp. 314–318, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. A. Inoue, K. Kobayashi, K. Usui et al., “First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1394–1400, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. F. Cappuzzo, C. Ligorio, P. A. Jänne et al., “Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2248–2255, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. H. L. West, W. A. Franklin, J. McCoy et al., “Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group study S0126,” Journal of Clinical Oncology, vol. 24, no. 12, pp. 1807–1813, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. D. H. Lee, J. Y. Han, H. G. Lee et al., “Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers,” Clinical Cancer Research, vol. 11, no. 8, pp. 3032–3037, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. T. S. Mok, Y. L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. J. S. Lee, K. Park, S. W. Kim, et al., “A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung,” in Proceedings of the World Conference on Lung Cancer, 2009, (abstract no. PRS.4).
  59. T. Mitsudomi, S. Morita, Y. Yatabe et al., “Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial,” The Lancet Oncology, vol. 11, no. 2, pp. 121–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Maemondo, A. Inoue, K. Kobayashi et al., “Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR,” The New England Journal of Medicine, vol. 362, no. 25, pp. 2380–2388, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. C. H. Yang, M. Fukuoka, T. S. Mok, et al., “Final overall survival results from a phase III, randomised, open-label, first-line study of gefitinib vs. carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS),” in Proceedings of the European Society of Medical Oncology Meeting, 2010, (abstract no. LBA2).
  62. M. Di Maio, C. Gallo, E. De Maio et al., “Methodological aspects of lung cancer clinical trials in the era of targeted agents,” Lung Cancer, vol. 67, no. 2, pp. 127–135, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. A. Morabito, M. Di Maio, E. De Maio, N. Normanno, and F. Perrone, “Methodology of clinical trials with new molecular-targeted agents: where do we stand?” Annals of Oncology, vol. 17, supplement 7, pp. vii128–vii131, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. R. A. Betensky, D. N. Louis, and J. G. Cairncross, “Influence of unrecognized molecular heterogeneity on randomized clinical trials,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2495–2499, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Mitsudomi, T. Kosaka, H. Endoh et al., “Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence,” Journal of Clinical Oncology, vol. 23, no. 11, pp. 2513–2520, 2005. View at Publisher · View at Google Scholar · View at PubMed
  66. C. Zhou, Y. I. Wung, G. Chen, et al., “Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations,” in Proceedings of the European Society of Medical Oncology Meeting, 2010, (abstract no. LBA13).
  67. C. Gridelli, F. Ciardiello, R. Feld, et al., “International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): the TORCH trial,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, (abstract no. 7508).
  68. R. Rosell, T. Moran, C. Queralt et al., “Screening for epidermal growth factor receptor mutations in lung cancer,” The New England Journal of Medicine, vol. 361, no. 10, pp. 958–967, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. S. Morita, I. Okamoto, K. Kobayashi et al., “Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations,” Clinical Cancer Research, vol. 15, no. 13, pp. 4493–4498, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. C. P. Belani, “The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors,” Cancer Investigation, vol. 28, no. 4, pp. 413–423, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus